The Data Can Speak for Itself
Applied Clinical Trials Editorial talks with CluePoints' Founder Marc Buyse about the history of CluePoints as well as the role of biostatistics in clinical trials
In this interview Applied Clinical Trials Editorial Director Lisa Henderson talks with CluePoints' Founder Marc Buyse. They discuss the history of CluePoints as well as the role of biostatistics: "The Data Can Speak for Itself
SPOTLIGHT EVENTRisk-Based Monitoring – Part Two In Depth ReviewMarch 13, 2014
Cambridge, MassachusettsDownload BrochureRegister
RELATED
- Snapshot Shows Targeted Site Monitoring Trend
- Risk-Based Approach to Monitoring
- Has FDA Guidance on Risk-based Monitoring Impacted SDV Coverage Yet?More in Risk-Based Monitoring
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
